# A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males

> **NCT02484729** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 196 (actual)

## Conditions studied

- Safety
- Tolerability
- Pharmacokinetics
- Healthy Subjects

## Interventions

- **DRUG:** AZD9977, oral suspension
- **DRUG:** Placebo, oral suspension
- **DRUG:** AZD9977, oral solution

## Key facts

- **NCT ID:** NCT02484729
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2017-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02484729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02484729, "A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02484729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*